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Background: Carcinomas of unknown primary (CUP) account for 3–5% of all
malignancy and, despite a reduction in incidence, the overall survival has not improved
over the last decade. Chemotherapy regimens have not provided encouraging results.
New diagnostic technologies, such as next generation sequencing (NGS), could
represent a chance to identify potentially targetable genomic alterations in order to
personalize treatment of CUP and provide insights into tumor biology.
Methods: A systematic review of studies of patients with CUP, whose tumor specimen
was evaluated through a NGS panel, has been performed on June 10th, 2019 according
to PRISMA criteria from PubMed, ASCO meeting library and Clinicaltrial.gov. We have
identified potentially targetable alterations for which approved/off-label/in clinical trials
drugs are available. Moreover, we have included case reports about CUP patients treated
with targeted therapies driven by NGS results in order to explore the clinical role of NGS
in this setting.
Results: We have evaluated 15 publications of which eleven studies (9 full-text articles
and 2 abstracts) have analyzed the genomic profiling of CUPs through NGS technology,
with different platforms and with different patients cohorts, ranging from 16 to 1,806
patients. Among all these studies, 85% of patients demonstrated at least one molecular
alteration, the most frequent involving TP53 (41.88%), KRAS (18.81%), CDKN2A (8.8%),
and PIK3CA (9.3%). A mean of 47.3% of patients harbored a potentially targetable
alteration for which approved/off-label/in clinical trials drugs were available. Furthermore,
we have identified 4 case reports in order to evaluate the clinical relevance of a specific
targeted therapy identified through NGS.
Conclusions: NGS may represent a tool to improve diagnosis and treatment of CUP by
identifying therapeutically actionable alterations and providing insights into tumor biology.
Keywords: cancer of unknown primary (CUP), next generation sequencing (NGS), genomic alterations,
comprehensive genomic profiling, targeted therapy
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INTRODUCTION
Carcinomas of unknown primary (CUPs) are a heterogeneous
group of metastatic tumors for which a standardized diagnostic
work-up fails to identify the site of origin at the time of diagnosis
(1). CUPs account for 3–5% of all malignancies (2, 3) and
disappointingly the overall survival in CUP population has not
improved over the last decades, despite advancements in the
knowledge of biology of solid tumors (4). This is partly due
to a lack of therapeutic options, with chemotherapy regimens
using either platinum or taxanes or both not having proved to
prolong survival in patient with CUP (5). Based on the available
categorization of CUPs into favorable and unfavorable groups
according to histopathological and clinical patterns (1, 6), great
efforts have been done to predict the organ tissue of origin of
CUPs through the IHC, DNA sequencing and gene expression
analyses with the aim to better customize therapy and possibly
improve clinical outcome (7–9). Based on the assumption that
a treatment directed to the molecularly predicted tissue of
origin could improve clinical outcome (10), a recent randomized
phase II trial comparing site-specific treatment based on gene
expression profiling vs. carboplatin and paclitaxel for patients
with CUP has been performed. This study however demonstrated
that site-specific therapy does not result in a significant survival
improvement compared with empirical chemotherapy (11),
leaving a clear unmet need for this patient population. Clinical
outcome of CUPs is unpredictable because, even if a primary
tumor does exist, they behave and metastasize unpredictably
from the known primary counterpart (6) and maybe this is their
real secret: their unknown biology rather than their unknown
primary. CUPs enigma is hidden in the molecular mechanism
that causes a fast cellular dedifferentiation and spreading (12).
The aim of this review is to describe genes and molecular
pathways involved in CUP pathogenesis and focus on available
data of targeted genotype-directed treatment in this setting.
METHODS
Data Sources and Search Strategy
A systematic literature review was performed on June 10th,
2019 according to PRISMA Criteria of 2009 (13) (Figure 1). We
reviewed PubMed, ASCOMeeting Library and ClinicalTrials.gov
for ongoing trials. The search criteria were limited to human
studies published in English language. The Medical Subject
Headings terms used for the search in PubMed were [(CUP OR
cancer of unknown primary) AND (NGS OR next generation
sequencing OR genomic alterations OR targeted therapies)]. The
Medical Subject Headings used for the search in ASCO Library
were [(“CUP” OR “cancer of unknown primary”) AND (“NGS”
OR “next generation sequencing” OR “genomic alterations” OR
“targeted therapies”)]. The Medical Subject Headings terms used
for the search in ClinicalTrials.gov were (“cancer of unknown
primary site” as condition/disease).
Selection Criteria
To be included in this review, a publication had to fulfill the
following inclusion criteria: study performed in patients with
cancer of unknown primary, whose tumor specimen could be
evaluated through a NGS panel. We also included case reports
and abstracts about CUP patients treated with targeted therapies
based on the NGS results provided. The exclusion criteria were:
publications written in language other than English and studies
using a method of genomic analysis different from NGS.
Article Analysis
Among the articles included in the systematic review according
to selection criteria, we evaluated all the studies performed in
patients with cancer of unknown primary, comparing the results
obtained through different NGS panels in each study, in order to
understand how many and what are the genomic alterations that
could be targeted with approved/off-label/in clinical trials drugs.
We also included case reports about CUP patients treated with
targeted therapies based on the NGS results provided, in order to
understand if NGS could represent a valid therapeutic option in
real life, improving the progression free survival and the response
rate of the disease.
RESULTS
We identified 794 records through database searching and 33
additional records through other sources (i.e., online meeting
library) (Figure 1). A total of 42 records were then screened
to be included in the systematic review. Twenty-seven records
were excluded for the following reasons: 5 were review
articles (4, 9–12), 15 studies evaluated CUP molecular profile
through techniques other than NGS (7, 14–27), 4 studies
took into account all solid tumors and it was not possible to
separate information about CUP population from other disease
conditions (28–31), 1 study evaluated the validity of NGS in
establishing a clonal relationship among metastasis and with an
antecedent malignancy in a CUP population (32) and 2 abstracts
contained few data to allow their inclusion in the review (33,
34). As a result, 15 publications were eligible and included in
the systematic review of which 9 full-text articles studies about
different CUP populations and their genomic alterations (35–43),
2 abstracts about CUPs and their genomic alterations (44, 45),
1 abstract about a case report in which NGS was performed
with subsequent therapeutic decisions tailored on NGS results
(46), 3 articles were case reports (47–49). Other 9 case reports
were extrapolated from the abovementioned full-text articles.
Table 1 displays studies included in the systematic review and
Table 2 shows the case reports, each with its own genomic
profile obtained through NGS and the subsequent response to
targeted therapy.
Eleven studies have analyzed the genomic profiling of CUPs
through Next Generation Sequencing technology, with different
platforms and with a different patients cohort, ranging from 16 to
1806 patients. Among all these studies (35–39), 85% of patients
demonstrated at least one molecular alteration, with a mean of
47.3% of patients harboring a potentially targetable alteration for
which approved/off-label/in clinical trials drugs were available.
The most frequent alterations involved TP53 (41.88%), KRAS
(18.81%), CDKN2A (8.8%), and PIK3CA (9.3%).
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FIGURE 1 | Flow diagram representing the systematic review process performed according to PRISMA Statement (13).
In the study by Ross et al. (35), one of the biggest in
this setting including 200 patients, 96% of cases harbored
at least one alteration and 85% of cases showed at least
one genomic alteration that could be targeted. The
most common clinically relevant alterations potentially
targetable included KRAS (20%), CDKN2A(19%), MCL1
(10%), PTEN (7%), PIK3CA (9%), ERBB2 (8%). Twenty-
six alterations were associated with targeted therapies
approved in a known primary tumor type; in 14 cases
there were alterations targetable with off-label drugs.
Furthermore, this study identified 6 cases showing activating
EGFRmutations.
In the study by Löffler et al. (36) the most frequently
mutated genes in CUP population were TP53 (55%), KRAS
(16%), CDKN2A (9%). In 15% of patients, they found
alterations targetable by currently approved drugs. Collaterally,
the investigators of this study observed that mutations of KRAS
and CDKN2A were associated with poor PFS and females with
wild type TP53 diseases had significantly better PFS and OS in
comparison with male population.
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TABLE 1 | Summary of full-text articles and abstracts of studies in CUP patients with reported genomic alterations as analyzed through different NGS panels and potentially matched drugs.
Tothill et al. (40) Gatalica et al.
(43)*
Ross et al. (35) Löffler et al.
(36)
Kato et al. (37) Subbiah et al. (38) Varghese
et al. (41)
Clynick et al. (39) Gatalica
et al. (42)
Varghese
et al. (45)
Chandler
et al. (44)
Matched drugs
N. pts 16 1806 200 55 442 17 150 17 389 34 CUP 35
Gene/Panel 701 genes 47 genes 287 genes 50 genes 54-70 genes,
ctDNA
255 genes 341-410
genes
2 gene panels, 76
genes
592 genes 341 genes 592 genes
TP53 10 38.0% 110 30 164 5 No numbers
provided.
The most
commonly
mutated
genes were
TP53, KRAS,
CDKN2A,
KEAP1 and
SMARCA4.
8 207/386 19 19 APR-246c
KRAS 2 (G12C) 18.0% 40 10 82 1 2 84/387 7 4 MEK-ia,c,
KRAS G12C-ic
CDKN2A 3 . 37 12 8 3 2 29/356 7 3 CDK4/6-i (e.g.,
abemaciclib)c
PIK3CA 3 (2 pts E81K -
VUS) (1 pt E545K)
8.0% 17 2 68 3 1 33/386 . 4 Alpelisiba,
AKT-ib,c,
mTOR-ic
AKT1 1 (E17K - VUS) 2.0% . 3 2 . . . present* . AKT-i (e.g.,
ipatasertib)b,c,
mTOR-ic
MET 1 (R400S - VUS) 4.0% 5 2 15 . 2 . . . MET TKIs (e.g.,
crizotiniba,c, tepotinibc )
FGFR1 . 0.0% 4 2 19 2 1 . . . FGFR-i (e.g.,
infigratinib, ponatinib,
rogaratinib)c
FGFR2 . . 4 . 4 . . . . . FGFR-i (e.g.,
erdafitiniba,c,
ponatinibc )
FGFR3 1 (T742I - VUS) . . 5 3 . . . . . FGFR-i (e.g.,
erdafitiniba,c,
rogaratinibc )
JAK2 1 (HLG) 0.0% . 1 1 . . 4/351 . . Ruxolitiniba,c
CCND1 1 (HLG) . . . 3 2 1 13/378 . . CDK4/6-ic
CCND2 . 4 . 2 . . . . . CDK4/6-ic
BRCA2 1 11.0% 11 . . 1 . 5/389 . . PARP-i (e.g.,
Olapariba,b,c,
Talazopariba,c )
BRCA1 3 (1 del) (2 SNV) 0.0% . . . . . 4/386 . . PARP-i (e.g.,
Olapariba,b,c,
Talazopariba,c )
(Continued)
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TABLE 1 | Continued
Tothill et al. (40) Gatalica et al.
(43)*
Ross et al. (35) Löffler et al.
(36)
Kato et al. (37) Subbiah et al. (38) Varghese
et al. (41)
Clynick et al. (39) Gatalica
et al. (42)
Varghese
et al. (45)
Chandler
et al. (44)
Matched drugs
PTCH1 1 (S1203Afs*52) . . . . . . 5/352 . . Vismodegibb
IDH1 1 (R132L) . . . . . . 7/387 . . Ivosideniba,c,
olutasidenibc
NOTCH1 3 . 5 . . 1 . 9/377 . . Bimiralisibc
MLH1 2 . . . 7 . 1 . . . Immune checkpoint-ic
MCL1 . . 19 . . 1 . 9/378 . . Seliciclib, MIK665c
PTEN . 3.0% 14 2 10 . . 15/371 . 2 Alpelisib, AKT-i,
mTOR-ic
ERBB2 . 2.0% 16 3 16 1 1 5/389 present* . antiHER2 (e.g.,
trastuzumab,
pertuzumab)a,b
RICTOR . . 12 . . . . . . . TORC1/2-i, mTOR-ic
BRAF . 3.0% 11 3 33 . 2 16/383 present* 3 BRAF-i+MEK-i (e.g.,
vemurafenib
+cobimetinib)b
NF1 . . 8 . . . . 7/340 . . mTOR-ic
EGFR 1 1.0% 6 3 26 . . 0 . . EGFR TKIs (e.g.,
erlotiniba,c,gefitiniba )
ALK . . 2 1 . 1 . . . . ALK-i (e.g., alectiniba,c,
brigatiniba )
RET . . 1 . 3 . . . . . RET-i (e.g., pralsetinibc,
selpercatinibc,
lenvatiniba )
STK11 3 6,0% 13 . 4 . . 18/387 . . mTOR-ic
ROS1 . . 1 . . . . . . . ROS1-i (e.g.,
entrectiniba,b )
TML-high . . . . . . . 46/389 . . Atezolizumabb,c
MSI-H . . . . . . . 7/389 . . Pembrolizumaba,c
Comments 12 alterations
potentially
targetable: 5 with
strong clinical
evidence of a drug
efficacy; 2
pre-clinical
evidence of a drug
efficacy; 5 with
limited evidence
96% alterations
with potential drug
benefit (mainly
through protein
biomarkers); 98%
alterations with
potential drug lack
of benefit
96% cases with at
least one alteration;
85% cases with
potentially
targetable
alterations: 26 with
approved therapies;
others with off-label
therapies or in clincal
trials
84% total
alterations of
which 15%
potentially
targetable
1368 total
alterations of
which 600 VUS.
688 alterations
potentially
targetable with
off-label drugs; 65
alterations
targetable with
drugs in clinical trials
88% cases with at
least one alteration.
65% cases
targetable alterations
with drugs in clinical
trial
30% cases
with
potentially
targetable
alterations
81% cases with at
least one alteration
of which 52%
potentially
targetable with
drugs approved for
another indication
or in clinical trials
28% cases
potentially
targetable by
immune
checkpoint-i
334 total
alterations.
41% cases
with potentially
targetable
alterations
*Absolute numbers not provided; aFDA/EMA approved in other indications; bUndergoing clinical evaluation for CUPs; cUndergoing clinical evaluation for other indications.
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TABLE 2 | Case reports of CUP patients with the genomic profile obtained through NGS panels and clinical outcome to matched targeted therapy.
References Histology and mutational profile provided by NGS Therapy Results
Ross et al. (35) Histology not specified, EML4-ALK fusion Crizotinib Best response: PR
Kato et al. (37) Adenocarcinoma of unknown primary (ACUP), KRAS G12D, MLH1 R389W
mutation
Trametinib+Nivolumab Best response: PR
Subbiah et al. (38) Squamous cell carcinoma of unknown primary, PIK3CA H1047R, KDM6A
S466, ALK L560F, CDC73 Q333, SOX2 amplification, CDK12 Q570
PI3K-i Best response: SD.
PFS = 6.5 months
ACUP, FBXW7 splice 726+1 G>A, APIP-NOTCH1 fusion, FGFR1
amplification, TP53 L45P, Q38fs79, ARID1A Y1211fs5, MYST3
amplification, ETV1 rearrangement
Carboplatin+bevacizumab+
temsirolimus
Best response: SD. PFS
> 8 months
Carcinoma of unknown primary (CUP), FBXW7 R465H, CCNE1
amplification, PIK3CA Q75E, TP53 R273C
Everolimus+anastrozole PD
CUP, FBXW7 W244, TP53 R248Q Sirolimus+hydroxychloroquine Best respone: SD.
PFS = 4.5 months
CUP, PIK3CA E545K and FGFR1 amplification, SOX2 amplification, KRAS
amplification, TP53 R196, CCND1 amplification, CDKN2A/B loss
Lenalidomide+temsirolimus PD
Squamous cell CUP, BRCA2 W1692fs3, ARID1A S1929fs25, CDKN2A/B
loss, EMSY amplification, MDM2 amplification, SMAD4 P130S, SOX2
amplification
Liposomial
doxorubicin+bevacizumab
+temsirolimus
PD
CUP, NF2 splice site 448-1G>A Lapatinib+sirolimus PD
Tan et al. (48) Poorly differentiated carcinoma, EGFR L858R Gefitinib Best response: PR.
PFS = 11 months
Palma et al. (47) Poorly differentiated carcinoma, EGFR WT, KRAS G12V mutation, MET
amplification, CCND1/MYC/TP53/CARD11 amplification
Crizotinib Best response:
CR. PFS = 19 months
Gröschel et al. (49) Poorly differentiated adenocarcinoma, TP53 E135fs, KRAS G12S,
mutations of uncertain significance in PI3KCD, CDKN2A,NCOA1, FAT2,
EGFR,ARID1A, overexpression of PDL1
Pembrolizumab Best response: Near CR
Zhao et al. (46) CUP, EML4-ALK fusion Crizotinib Best response: PR
In order to overcome both genomic heterogeneity between
the primary tumor and all the metastatic lesions and temporal
molecular changes occurring during sequential therapies, Kato
et al. (37) analyzed the genomic profile of a CUP population
of 442 patients using NGS applied on circulating tumor DNA
(ctDNA). They found at least a genomic alteration in the 80%
of cases, the most common of which interesting TP53 (37%),
KRAS (18%) and PIK3CA (15%). Though, approximately 44%
of the abovementioned alterations were variants of unknown
significance (VUS). 50% of 1368 alterations were potentially
targetable with off-label/in clinical trial drugs, whereas 63.8% of
patients showed an alteration targetable with an FDA-approved
agent. With this retrospective study Kato et al. demonstrated
how the tumor molecular evolution during several lines of
therapies could be pursued using NGS on ctDNA, with the
possibility to customize the therapy time by time, also avoiding
invasive biopsies.
In the study by Gatalica et al. (43) the most commonly
mutated genes were TP53 and KRAS (38 and 18%, respectively),
followed by BRCA2, PIK3CA, and STK11 (with a frequency
≥5%); themost commonly amplified genes were EGFR andHER2
(17 and 5%, respectively).
In other three studies by Tothill et al. (40), Subbiah et al. (38),
and Clynick et al. (39), 75, 65, and 52%, potentially targetable
alterations with approved/approved for another indication/in
clinical trials drugs were found, respectively. The most common
clinically relevant alterations detected in these studies included
ERBB2, EGFR, KRAS, PIK3CA, and BRAF. Clynick et al. used two
different gene panels, each one detecting a different number of
alterations, 8 alterations were detected by both panels. Subbiah
et al. also evaluated the clinical response in 7/17 patients who
received a therapy matched to molecular aberrations (Table 2):
the best tumor responses were stable disease lasting up to 6
months in 3 patients and 1 remaining on therapy for over
8 months.
In the study by Varghese et al. (41), including 150 patients,
54 potentially targetable alterations were identified in 45 patients.
Themost commonlymutated genes were TP53, KRAS, CDKN2A,
KEAP1, and SMARCA4. Twenty-seven targetable alterations with
FDA-approved drugs for another indication were found in 23
tumors (most common ERBB2 amplification and BRAF V600E
mutation); 27 alterations targetable with drugs for which a
clinical evidence exists but in another indication were found
in 25 tumors (most common PIK3CA mutation); 32 alterations
targetable with drugs for which preclinical evidence exists were
found in 38 tumors (the most common KRASmutation). Fifteen
patients in the study received a targeted therapy shown to
be active in patients with BRAF V600E mutations, ERBB2
amplification, KIF5B-ALK fusion and NCOA4-RET fusion.
Among them, results in terms of time to treatment failure (TTF)
were variable, ranging from <1 month to 14 months, and several
patients remaining on therapy at the time of data cut-off.
Gatalica et al. (42) studied a CUP population of 389 patients
in which tumor mutational load (TML) and microsatellite
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instability (MSI) were evaluated through NGS, while PD-L1
expression using immunohistochemistry (with 5% cut-off value).
High TML was detected in approximately 12% of patients,
MSI-high (MSI-H) in 2% of patients, expression of PD-L1
>5% in 22% of cases. Furthermore, predictive biomarkers of
hyperprogression to immune checkpoint inhibitors, including
MDM2 gene amplification and loss-of-function JAK2 gene
mutations, were identified in 2 and 1% of cases, respectively.
Finally, in the study by Chandler et al. (44), in a population of
different solid tumors of which 1,172 samples could be analyzed
with NGS, CUPs represented the 3%, and among these, the
most frequently alterations interested TP53 (54%), KRAS (11%),
PIK3CA (11%), BRAF (9%). Also in the study by Varghese
et al. (45), in a population of 34 patients, 334 alterations were
identified, most commonly in TP53 (19/34), CDKN2A (7/34),
KRAS (7/34); potentially targetable alterations were identified in
14/34 of patients and included BRAF V600E, ERBB2 S310F, and
AKT1 E17K.
In the absence of prospective clinical trials, the clinical
relevance of a specific targeted therapy identified through NGS, is
coming from case reports. Table 2 displays case reports retrieved
in this systematic review.
DISCUSSION
Results of this systematic review from nine published studies
and two abstracts show that 85% of patients with CUP harbor
in their tumor at least one identified genomic alteration,
including variants of uncertain significance (VUS), and that
47.3% of them present a potentially targetable alteration for
which approved/off-label/in clinical trials drugs are available.
The most frequent alterations were found in TP53, KRAS,
CDKN2A, PIK3CA; interestingly none of the patients had
two identical molecular profiles underlying the assumption
that CUPs are an individually heterogeneous molecular and
clinical entity.
Although there are no targeted therapies, TP53 is one of the
most frequently altered gene in CUPs. This molecular alteration
appears to be associated with highVEGF-A levels (50) and clinical
data suggest that patients with TP53 mutations have better
progression-free survival (51) and improved clinical outcome
with anti-VEGF drugs (52) in comparison with patients with
wild-type TP53. RAS-driven tumors are potentially targetable
with MEK inhibitors (e.g., trametinib and cobimetinib) (53)
and some ongoing trials are evaluating the activity of different
drugs against KRAS G12C mutation (54, 55), while PIK3CA
mutations have been shown to be associated with response in
45% in patients with advanced cancers when treated with a PI3K
inhibitor or mTOR inhibitors (56); further, the specific inhibitor
alpelisib has recently gained FDA-approval for breast cancer (57).
Until now,measuring the clinical value of the genomic alterations
identified in the CUP population has been elusive, because only
case reports are available about targeted therapies customized
according to individual genomic profiles (Table 2). The ongoing
clinical trials will better elucidate the clinical validity of this
approach for CUPs (Table 3).
TABLE 3 | Recruiting studies available for CUP population.
Study (study ID)
Phase
Main location
NGS Drugs
A Phase II Randomized Study Comparing
the Efficacy and Safety of Targeted Therapy
or Cancer Immunotherapy vs.
Platinum-Based Chemotherapy in Patients
With Cancer of Unknown Primary Site
(CUPISCO)
Phase II
116 study locations
Yes Alectinib
Vismodegib
Ipatasertib
Olaparib
Erlotinib
Bevacizumab
Vemurafenib
Cobimetinib
Trastuzumab
Pertuzumab
Atezolizumab
Carboplatin
Paclitaxel
Cisplatin
Gemcitabine
Trial of Pembrolizumab in Cancer of
Unknown Primary (CUPem)
Phase II
London, United Kingdom
No Pembrolizumab
Tissue-of-origin Directing Therapy in
Patients With Cancer of Unknown Primary
Phase III
Shangai, China
No Standard treatments
based on tissue-of-origin
(ORIGIN-PanCA◦R)
profiling vs. standard
empiric chemotherapy
Ontario-wide Cancer TArgeted Nucleic Acid
Evaluation (OCTANE)
Observational
Ontario, Canada
Yes __
Genomic Investigation of Unusual
Responders (GENIUS)
Observational
Ontario, Canada
Yes __
Pembrolizumab in Patients With
Poor-Prognosis Carcinoma of Unknown
Primary Site (CUP) (CUP)
Phase II
Alberta, Canada
No Pembrolizumab
Potential limitations of a tissue-agnostic therapeutic approach
include that extrapolating therapeutic actionability from
one cancer histology to another might provide uncertain
results: for example, known differences exist in the clinical
activity of BRAF inhibitors in melanoma and colorectal cancer
(58, 59) and in the efficacy of HER2-directed treatments
in breast as compared to gastric (60, 61) or colorectal
cancers (62). Therefore, for CUP patients it would be still
important to consider putative primary sites even when
candidate actionable driver mutations are found. Finally, we
should take into account that redundancy in activation of
pathways of resistance does often take place as a mechanism
of primary as well as secondary resistance (63, 64), for
example through the co-activation of two or more antagonist
pathways, affecting opportunities for a targeted pharmacological
blockade (29). Liquid biopsies have a high sensitivity and
specificity in reflecting the onset of resistance mutations
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as well as in detecting tumors alterations (65) and they
could be used for these goals. Kato et al. (37) observed
that NGS on blood-based biopsies can reveal clinically
relevant genomic alterations in CUPs, occurring during
different lines of therapy, enabling precision medicine, and
liquid biopsy may also reflect the biological heterogeneity
of the tumor in time and between the primary and the
metastatic sites, providing more insights in CUPs biology and
natural history.
Based on the assumption that, as far as they can evolve,
metastatic lesions should retain the signature of the primary
tumor (66), several trials have been performed using gene
expression profiling techniques such as RT-PCR assay (10, 67)
or using epigenetics by identifying the DNA methylation profile
of the primary (15, 68), in order to identify the potential tissue
of origin and drive therapy accordingly. However, based on the
recent study by Hayashi et al. (11) it is still questionable whether
a site-specific chemotherapy is beneficial and further studies are
needed to define this point.
Multiple oncogenic pathways have been investigated in order
to understand their contribution in pathogenesis of CUPs, their
prognostic value and value as therapeutic targets. With this
regard, we found that the most frequent alterations in CUPs
involve TP53, KRAS, CDKN2A, PIK3CA. Pentheroudakis et al.
(69) and Kampsorias et al. (70) did not find a prognostic value
by analyzing the expression of TP53, RAS, C-Myc, and Bcl-2,
as well as EGFR or HER2 overexpression; furthermore, they
noticed that the incidence of tumor suppressor and DNA repair
gene inactivation in CUPs is similar to that reported in other
solid tumors with a known primary site. According to Löffler
et al. (36), mutations of KRAS and CDKN2A are associated
with poor PFS, while wild type TP53 in females has a positive
prognostic value associated to a significantly better PFS and OS
in comparison with male population. Karvasilis et al. (18) also
studied the tissue expression of VEGF and TSP-1 in CUPs, the
first with a role of activator of angiogenesis and the second
as an endogenous inhibitor of the process and they found a
negative association between TSP-1 expression and microvessel
density, suggesting that TSP-1 can correlate with a favorable
prognosis, furthermore, microvessel density was low in the group
of favorable CUPs, but none of the abovementioned factors
showed a prognostic value. Stella et al. (71) evaluated the role of
MET in a heterogeneous population with a known or unknown
primary. MET activation is a late event in tumorigenesis, after
the onset of unfavorable microenvironmental conditions, and
it was found to be mutated in all CUPs samples, associated
with a negative prognosis; in our review we found that MET
alterations are present in 2.7% of cases (35–37, 39, 40, 43)
and, as demonstrated in a case report (35, 47), the targeted
agent Crizotinib is associated with a better outcome in this
setting. Gatalica et al. (43) noticed that the overexpression
of two topoisomerases (Topo1 and Topo2alfa), identified
through immunohistochemistry analysis, was associated with
a potential benefit using cytotoxic therapies; on the contrary,
the overexpression of multidrug resistance–associated protein
1 (MRP1) and the overexpression of breast cancer resistance
protein (BCRP), a member of the ABC transporter proteins,
were associated to a potential drug lack of benefit. Also the
microenvironment could play a role in determining a dormancy
of the primary tumor cells (72), as well as metalloproteinases
allowing tumor cells migration (70) and Programmed Death-
1 (PD-1) T cell co-receptor and its ligands, B7-H1/PD-L1
and B7-DC/PD-L2, maintaining an immunosuppressive tumor
microenvironment (73). Gatalica et al. (42, 43) found that PD-
L1 expression, detected through immunohistochemistry (with
5% cut-off value), was present in 22% of cases; while a high
TML, detected through NGS, was expressed in 12% of patients
and MSI-H status in 2% of patients. Ongoing clinical trials are
evaluating the clinical impact of immune checkpoint inhibitors
in CUP population (Table 3).
Altogether these data highlight the absence of an established
distinguishing underlying molecular biology make-up of CUPs,
confirming that their molecular pathogenesis is complex and
heterogeneous. In order to overcome this lack of knowledge, NGS
represents a chance, although not validated by clinical trials, to
improve diagnosis andmatched treatment of potential actionable
molecular alterations.
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